Inoviem Scientific provides pharmaceutical companies with key information on drug–target interactions to support decision-making from drug discovery through pre-clinical and clinical stages to post-marketing. Its core technologies are the label-free NPOT® and PIMS®, which operate on human tissue in clinical conditions. The company is led by president and founder Dr. Pierre Eftekhari. It plans to use newly raised funds to broaden its range of services and to finance a move to larger laboratory facilities in the Illkirch-Graffenstaden innovation park. The article notes prior funding of more than €1 million in 2015 from Cap Innov’Est and Bpifrance. Current reporting does not disclose operating metrics such as revenue or user counts. Inoviem Scientific is an innovation- and technology-driven contract research biotech (CRB) founded in 2011 by Dr. Pierre Eftekhari in Strasbourg, France. It leverages two proprietary technologies, including NPOT (Nematic Protein Organization Technique), to help pharmaceutical and biotechnology clients increase speed and safety across drug discovery and clinical trials. Its services span identification of secondary targets, detection of potential adverse effects, patient stratification, and biomarker identification. The company plans to develop and automate its existing innovative technology and further 'label-free' technologies under physiological conditions, and to automate NPOT to increase sample throughput and revenue potential. Financially, Inoviem received €545k (approx. $611k) in funding from French public investment bank bpifrance. The financing comprises a €295k zero-interest innovation loan and a €250k France Europe Innovation (FEI) loan. Inoviem Scientific is a contract research biotech that leverages two proprietary technologies to support pharmaceutical drug development from discovery through clinical trials. Its platform is used for tasks such as identification of primary and secondary targets, detection of potential adverse effects, patient stratification and biomarker identification. The company has signed five agreements with pharmaceutical and biotechnology firms. At the start of 2015 it opened an office in Frankfurt to grow its business in the German, Austrian and Benelux markets. Led by founder and chairman Dr. Pierre Eftekhari, Inoviem plans to put its technologies into production and enter the broader European market over the next 12 months. It also intended to increase staff by 50% in 2015.

Total raised

$2M

Funding rounds

5

Latest round

Equity

Latest activity

Apr 2017